Multiple myeloma in renal transplant recipients
- Authors: Rekhtina IG1, Biryukova LS1, Varshavsky VA2, Golitsina GP2, Savchenko VG1
-
Affiliations:
- Hematology Research Center, Russian Academy of Medical Sciences, Moscow
- I. M. Sechenov Moscow Medical Academy, Moscow
- Issue: Vol 82, No 7 (2010)
- Pages: 76-79
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30657
- ID: 30657
Cite item
Full Text
Abstract
About the authors
I G Rekhtina
Hematology Research Center, Russian Academy of Medical Sciences, Moscow
Email: rekhtina@blood.ru
Hematology Research Center, Russian Academy of Medical Sciences, Moscow
L S Biryukova
Hematology Research Center, Russian Academy of Medical Sciences, Moscow
Email: birjurova@blood.ru
Hematology Research Center, Russian Academy of Medical Sciences, Moscow
V A Varshavsky
I. M. Sechenov Moscow Medical Academy, Moscow
Email: Vavarsh@mmscience.ru
I. M. Sechenov Moscow Medical Academy, Moscow
G P Golitsina
I. M. Sechenov Moscow Medical Academy, Moscow
Email: golicina@mail.ru
I. M. Sechenov Moscow Medical Academy, Moscow
V G Savchenko
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
References
- Alexanian R., Barlogie B., Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch. Intern. Med. 1990; 150: 1693-1695.
- Knudsen L., Hippe E., Hjorth M. et al. Renal function in newly diagnosed multiple myeloma - a demographic study of 1353 patients. Eur. J. Haematol. 1994; 53: 207-212.
- Torra R., Blade J., Cases A. et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br. J. Haematol. 1995; 91: 854-859.
- Everly M. J., Everly J. J., Susskind B. et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86 (12): 1754-1761.